
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. has shown a positive financial trajectory, with a reported top-line revenue of $191.8 million for Q3 2025, reflecting a 10% quarter-over-quarter increase and a 5% year-over-year increase, surpassing market expectations. The company anticipates high-single digit unit growth for Baqsimi in 2025, driven by a successful sales collaboration and seasonal demand, along with strong performance from Primatene Mist that is expected to benefit from fall and winter usage. Furthermore, Amphastar projects a return to double-digit growth in 2026 despite current variations in the sales of glucagon and epinephrine products.
Bears say
Amphastar Pharmaceuticals Inc. is experiencing significant downward revisions in its sales forecasts, particularly for its iron sucrose and glucagon products, which are now projected to generate considerably lower revenues than initially anticipated due to increased market competition and supply challenges. The pharmaceutical company is facing a challenging competitive landscape, with glucagon sales expected to decline below $70 million as new competitors continue to enter the market, further impacting revenue projections. Additionally, expectations for a robust return to double-digit top-line growth in 2026 have been tempered, with prospects now leaning towards only moderate growth in the high-single digit to low-double digit range, raising concerns about the overall health of the company's future earnings prospects.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares